文献速递肝病

卡维地洛的使用与肝硬化腹水患者生存改善相关

Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites.
PubMed 文献 · J Hepatol · 2017-02-16

单中心回顾性分析325例肝硬化腹水患者,经倾向评分匹配后264例分为卡维地洛组与非卡维地洛组各132例,中位随访2.3年。卡维地洛组随访末生存率为24%,非卡维地洛组为2%(log-rank p<0.0001)。校正混杂因素后,卡维地洛与死亡率降低相关(HR 0.59,95%CI 0.44-0.80;p=0.001)。

要点

  • 卡维地洛组随访末生存率24%,非卡维地洛组2%(log-rank p<0.0001)。
  • 校正后卡维地洛与死亡率降低相关,HR 0.59(95%CI 0.44-0.80;p=0.001)。
  • 轻度腹水患者中卡维地洛HR 0.47(95%CI 0.29-0.77;p=0.003),中重度腹水不增加死亡风险。

核心结论

  • 长期卡维地洛治疗对失代偿期肝硬化腹水患者无害,且与死亡率降低相关,尤其在轻度腹水患者中。

研究设计与样本

  • 单中心回顾性分析,纳入2009年1月1日至2012年8月31日连续325例肝硬化腹水患者,经倾向评分匹配后最终队列264例,卡维地洛组与非卡维地洛组各132例。

主要发现

  • 卡维地洛组与非卡维地洛组基线腹水严重程度和UKELD评分可比,中位随访时间2.3年。
  • 随访末生存率卡维地洛组24% vs 非卡维地洛组2%(log-rank p<0.0001),卡维地洛组长期生存显著优于非卡维地洛组(log-rank p<0.001)。
  • 校正年龄、性别、腹水严重程度、肝硬化病因、既往静脉曲张出血、自发性细菌性腹膜炎预防、血清白蛋白和UKELD后,生存差异仍显著,HR 0.59(95%CI 0.44-0.80;p=0.001),相当于死亡风险降低41%。
  • 按腹水严重程度分层,轻度腹水患者卡维地洛治疗HR 0.47(95%CI 0.29-0.77;p=0.003)。
  • 中重度腹水患者使用卡维地洛与死亡风险增加无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Carvedilol, a non-selective beta-blocker (NSBB) with additional anti-alpha 1 receptor activity, is a potent portal hypotensive agent and has been used as prophylaxis against variceal bleeding. However, its safety in patients with decompensated liver cirrhosis and ascites is still disputed. In this study, we examined whether long-term use of carvedilol in patients with ascites is a risk factor for mortality. METHODS: A single-centre retrospective analysis of 325 consecutive patients with liver cirrhosis and ascites presenting to our Liver Unit between 1st of January 2009 to 31st August 2012 was carried out. The primary outcome was all-cause and liver-specific mortality in patients receiving or not receiving carvedilol as prophylaxis against variceal bleeding. RESULTS: The final cohort after propensity score matching comprised 264 patients. Baseline ascites severity and UK end-stage liver disease (UKELD) score between carvedilol (n=132) and non-carvedilol (n=132) treated patient groups were comparable. Median follow-up time was 2.3years. Survival at the end of the follow-up was 24% and 2% for the carvedilol and the non-carvedilol groups respectively (log-rank p<0.0001). The long-term survival was significantly better in carvedilol than non-carvedilol group (log-rank p<0.001). The survival difference remained significant after adjusting for age, gender, ascites severity, aetiology of cirrhosis, previous variceal bleed, spontaneous bacterial peritonitis prophylaxis, serum albumin and UKELD with hazard ratio of 0.59 (95% confidence interval [CI]: 0.44, 0.80; p=0.001), suggesting a 41% reduction in mortality risk. When stratified by the severity of ascites, carvedilol therapy resulted in hazard ratio of 0.47 (95% CI: 0.29, 0.77; p=0.003) in those with mild ascites. Even with moderate or severe ascites, carvedilol use was not associated with increased mortality risk. CONCLUSION: Long-term carvedilol therapy is not harmful in patients with decompensated cirrhosis and ascites. LAY SUMMARY: The safety of carvedilol and other non-selective beta-blocker drugs in patients with liver cirrhosis and ascites is still debated. In this study, we have shown that carvedilol therapy in these patients was associated with reduced risk of mortality, particularly in those with mild ascites. We concluded that low dose, chronic treatment with carvedilol in patients with liver cirrhosis and ascites is not detrimental.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Sinha R, Lockman KA, Mallawaarachchi N, et al. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. J Hepatol. 2017. PMID: 28213164. doi:10.1016/j.jhep.2017.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。